Sat Kartar Stock Price Today (NSE: SATKARTAR)
Fundamental Score
Sat Kartar Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Sat Kartar share price today is ₹160.20, up +3.42% on NSE/BSE as of 22 September 2026. Sat Kartar (SATKARTAR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹208.66 (Cr). The 52-week high for SATKARTAR share price is ₹168.80 and the 52-week low is ₹110.30. At a P/E ratio of 12.09x, SATKARTAR is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 28.97% and a debt-to-equity ratio of 0.04.
Sat Kartar Share Price Chart — NSE/BSE Historical Performance
Sat Kartar share price chart: -4.59% return over the past month. 52-week high ₹168.80, 52-week low ₹110.30.
Sat Kartar — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹148.70 | ₹165.00 | ₹143.00 | ₹154.90 | 2.06L (Cr) | |
| ₹143.00 | ₹146.90 | ₹142.00 | ₹142.90 | 32.80K (Cr) | |
| ₹147.45 | ₹147.50 | ₹134.90 | ₹139.15 | 30.40K (Cr) | |
| ₹150.80 | ₹150.80 | ₹140.00 | ₹143.30 | 29.60K (Cr) | |
| ₹147.00 | ₹159.20 | ₹135.00 | ₹144.85 | 1.40L (Cr) | |
| ₹137.00 | ₹148.00 | ₹135.25 | ₹145.20 | 1.65L (Cr) | |
| ₹117.00 | ₹133.30 | ₹116.00 | ₹131.20 | 79.20K (Cr) | |
| ₹118.00 | ₹119.90 | ₹113.00 | ₹116.40 | 38.40K (Cr) | |
| ₹116.05 | ₹117.00 | ₹110.30 | ₹117.00 | 20.80K (Cr) | |
| ₹118.00 | ₹118.15 | ₹116.05 | ₹116.05 | 15.20K (Cr) |
Sat Kartar — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹126.00 | ₹165.00 | ₹110.30 | ₹154.90 | +22.94% | |
| ₹119.00 | ₹154.00 | ₹112.00 | ₹125.40 | +5.38% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Sat Kartar Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sat Kartar Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SATKARTAR across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (28.97%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (37.42%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 12.09 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (58.10%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (21.07%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (46.76x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (63.62%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Limited Institutional Interest (FII+DII: 2.39%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Sat Kartar vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Sat Kartar with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Sat KartarSat Kartar...Selected✓ SATKARTAR • | 54.9/100 | ₹160.20₹160 | ₹208.66₹208.66 | 12.09Average 12.1 Average | 28.97%Excellent 28.97% Excellent | 37.42%Excellent 37.42% Excellent | 0.04Excellent 0.0 Excellent | — — | — — | 0.53% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Sat Kartar Quarterly Performance
Latest quarterly metrics for SATKARTAR — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
21.07%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
58.10%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Sat Kartar Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SATKARTAR — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Sat Kartar Financial Statements
Annual income statement, balance sheet and cash flow for Sat Kartar (SATKARTAR) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Sat Kartar
About SATKARTAR (Sat Kartar)
Sat Kartar (SATKARTAR) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current ma...rket capitalisation of ₹208.66 (Cr). Sat Kartar has delivered a Return on Equity (ROE) of 28.97% and a ROCE of 37.42%. The debt-to-equity ratio stands at 0.04, reflecting the company's capital structure. Investors tracking SATKARTAR share price can monitor key metrics including P/E ratio, promoter holding of 63.62%, and quarterly earnings growth.
Company Details
SATKARTAR Share Price: Frequently Asked Questions
What is the current share price of Sat Kartar?
Sat Kartar (SATKARTAR) trades at ₹160.20 on NSE. Market cap ₹208.66 (Cr). Educational data only.
What is the P/E ratio of Sat Kartar?
Sat Kartar has a P/E of 12.09x vs industry average 34.89x.
What is the Bull Run score for Sat Kartar?
Sat Kartar has a Bull Run score of 54.9/100 based on 25+ financial parameters.
Does Sat Kartar pay dividends?
Sat Kartar has a dividend yield of 0.53%. Past dividends don't guarantee future payments.
What is the ROE of Sat Kartar?
Sat Kartar has ROE of 28.97%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Sat Kartar?
Sat Kartar has debt-to-equity of 0.04.
Is Sat Kartar a good investment?
Bull Run gives Sat Kartar a score of 54.9/100. This is not investment advice — consult a SEBI-registered advisor.